- December 23, 2021
- Posted by: Stratford Team
- Category: Business
There’s no denying that the biggest biosimilars story in 2021, and most likely in 2022, is adalimumab and how biosimilars of the reference drug (Humira) are going to perform.
Market for Yuflyma
Among the business headlines that generated the most clicks in 2021 was an interview with HoUng Kim, PhD, head of the Medical and Marketing Division at Celltrion Healthcare in Republic of Korea. Kim talked about the market for Yuflyma (CT-P17), Celltrion’s adalimumab high concentration, citrate-free biosimilar. This product in February 2021 gained the European Commission’s approval for commercialization in the European Union.
Celltrion planned a June market launch in 6 countries in the European Union and 7 more countries in the third quarter of this year. Before this, the market for high-concentration adalimumab had been exclusive to reference product maker AbbVie. Yuflyma allows low-volume administration, and its citrate-free quality reduces pain upon…
